146 related articles for article (PubMed ID: 36915871)
1. Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen.
Deng L; Yue D; Wang X; Li H
Transl Androl Urol; 2023 Feb; 12(2):261-270. PubMed ID: 36915871
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
[TBL] [Abstract][Full Text] [Related]
3. Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.
Kaufmann B; Pellegrino P; Zuluaga L; Ben-David R; Müntener M; Keller EX; Spanaus K; von Eckardstein A; Gorin MA; Poyet C
Eur Urol Open Sci; 2024 May; 63():4-12. PubMed ID: 38558765
[TBL] [Abstract][Full Text] [Related]
4. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
7. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Martin BJ; Finlay JA; Sterling K; Ward M; Lifsey D; Mercante D; Jainto JM; Martin L; Rayford W
Prostate Cancer Prostatic Dis; 2004; 7(2):132-7. PubMed ID: 15007379
[TBL] [Abstract][Full Text] [Related]
8. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
[TBL] [Abstract][Full Text] [Related]
9. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
10. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.
Ferraro S; Biganzoli G; Bussetti M; Castaldi S; Biganzoli EM; Plebani M
Clin Chem Lab Med; 2023 Jan; 61(1):142-153. PubMed ID: 36322977
[TBL] [Abstract][Full Text] [Related]
11. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
12. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
13. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
Slev PR; La'ulu SL; Roberts WL
Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
[TBL] [Abstract][Full Text] [Related]
14. The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
Garrido MM; Ribeiro R; Pinheiro LC; Holdenrieder S; Guimarães JT
Clin Chem Lab Med; 2021 Oct; 59(11):1869-1877. PubMed ID: 34318651
[TBL] [Abstract][Full Text] [Related]
15. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
[TBL] [Abstract][Full Text] [Related]
18. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
[TBL] [Abstract][Full Text] [Related]
19. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
20. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
